Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Published 04/11/2024, 01:01 PM
Updated 04/12/2024, 11:26 AM
© Reuters. CEO of AstraZeneca Pascal Soriot speaks at an announcement at AstraZeneca in Mississauga Ontario, Canada February 27, 2023. REUTERS/Carlos Osorio/File Photo
UK100
-
AZN
-
SHEL
-
AZN
-

(Reuters) -AstraZeneca shareholders on Thursday approved a 2024 pay policy which will boost CEO Pascal Soriot's remuneration to as much as 18.9 million pounds ($23.7 million) this year, but over a third of investors revolted against the huge sum.

High executive pay in Britain has long been contentious, particularly with pay for ordinary workers rising far more slowly, and Soriot's pay package has proved a lightning rod for investor discontent in the past.

In 2021 — the last time AstraZeneca (NASDAQ:AZN)'s long-term incentives policy was reviewed — almost 40% of votes were cast against it, and proxy advisory groups Glass Lewis and ISS also opposed the plan, as they did this year.

Of the 1.18 billion total votes cast on Thursday, 64.43% were in favour and 35.57% were against the resolution that will take Soriot's maximum annual bonus for 2024 to three times his base salary, and make him eligible for long-term performance-based share awards worth as much as 8.5 times his salary.

Soriot was handed 16.9 million pounds last year after hitting most long-term targets.

Despite the notable no votes, the final result is a major boost to one of the best-paid executives among London's blue-chip FTSE 100 at a time when British firms are looking to match U.S. and European rivals' pay packages.

AstraZeneca has defended the pay policy, saying the changes are necessary to increase competitiveness against its European peers and recognise leadership's critical role in achieving its long-term targets.

Since taking the helm in 2012, Soriot has transformed AstraZeneca into the UK's second-most-valuable listed company after Shell (LON:SHEL).

Earlier on Thursday, the drugmaker announced a 7% hike to 2024 dividend payouts, betting on a strong performance and cash generation from its blockbuster drugs and several recent acquisitions.

© Reuters. CEO of AstraZeneca Pascal Soriot speaks at an announcement at AstraZeneca in Mississauga Ontario, Canada February 27, 2023. REUTERS/Carlos Osorio/File Photo

Its shares have outpaced rival GSK's and the broader pharma index in recent years. Shares have risen 85% since Jan. 1 2019, compared with GSK's 8% rise.

($1 = 0.7973 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.